{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-057501","form_type":"8-K","ticker":"JAGX","cik":"0001585608","company_name":"Jaguar Health, Inc.","filed_at":"2023-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.541988+00:00","generated_at":"2026-06-15T09:09:17.324387+00:00","sec_items":["1.01","5.03","2.03","3.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Jaguar Health completes enrollment in pivotal Phase 3 OnTarget trial; raises $1.86M in PIPE financing","bullets":["Enrolled target 256 patients in Phase 3 OnTarget trial for crofelemer to prevent cancer therapy-related diarrhea; top-line results expected early Q4 2023.","Private placement raises ~$1.86M via 137 Series G convertible preferred shares (convertible at $0.5423) and 6,850,000 warrants at $0.48 exercise price.","Warrants exercisable from later of Jan 1, 2024 or stockholder approval, for 5 years; no anti-dilution or variable pricing.","Standstill agreement with Iliad, Uptown, Streeterville suspends royalty payments for up to 6 months; they receive warrants for ~3.82M shares.","Company agrees not to issue additional equity securities before Oct 22, 2023, except with PIPE investor consent."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-057501","json":"https://secwatch.observer/filing/0001104659-23-057501.json","markdown":"https://secwatch.observer/filing/0001104659-23-057501.md","text":"https://secwatch.observer/filing/0001104659-23-057501.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1585608/000110465923057501/0001104659-23-057501-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1585608/000110465923057501/tm2315061d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T09:09:17.324387+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d7f95740845429f38c068e00af6b0875a5c43ef8","claim":"Jaguar Health, Inc.: Created Series G Preferred Stock via Certificate of Designation, establishing its preferences, rights, and limitations.","evidence_excerpt":"Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. Series G Certificate of Designation As disclosed under Items 1.01 and 3.02 above, in connection with the Private Placement, the Company agreed to issue the Series G Preferred Stock to the Purchasers. The preferences, rights, limitations and other matters relating to the Series G Preferred Stock are set forth in the Certificate of Designation.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1585608/000110465923057501/0001104659-23-057501-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}